ABBOTT LABORATORIES

ABT 10-K · Q4 2025
API behind this page

ABT Q4 2025 request

Playground key active
Request URL /api/financials?ticker=ABT&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 11,459 10,974 +4.4%
Show Product Lines breakouts
COVID-19 Testing · Diagnostics 89 176 -49.4%
Show Business Segments breakouts
Diagnostics · Core Laboratory 1,461 1,387 +5.3%
Diagnostics · Molecular 141 137 +2.9%
Diagnostics · Non Us 1,490 1,465 +1.7%
Diagnostics · Non Us 1,085 1,024 +6.0%
Diagnostics · Non Us 102 99 +3.0%
Diagnostics · Non Us 51 47 +8.5%
Diagnostics · Non Us 252 295 -14.6%
Diagnostics · Operating Segments 2,457 2,520 -2.5%
Diagnostics · Point of Care 158 147 +7.5%
Diagnostics · Rapid Diagnostics 697 849 -17.9%
Diagnostics · US 967 1,055 -8.3%
Diagnostics · US 376 363 +3.6%
Diagnostics · US 39 38 +2.6%
Diagnostics · US 107 100 +7.0%
Diagnostics · US 445 554 -19.7%
Established Pharmaceuticals · Key Emerging Markets 1,046 948 +10.3%
Established Pharmaceuticals · Non Us 1,382 1,268 +9.0%
Established Pharmaceuticals · Non Us 1,046 948 +10.3%
Established Pharmaceuticals · Non Us 336 320 +5.0%
Established Pharmaceuticals · Operating Segments 1,382 1,268 +9.0%
Established Pharmaceuticals · Other 336 320 +5.0%
Medical Devices · Diabetes Care 2,133 1,863 +14.5%
Medical Devices · Electrophysiology 730 643 +13.5%
Medical Devices · Heart Failure 375 331 +13.3%
Medical Devices · Neuromodulation 274 257 +6.6%
Medical Devices · Non Us 3,070 2,699 +13.7%
Medical Devices · Non Us 1,290 1,129 +14.3%
Medical Devices · Non Us 390 343 +13.7%
Medical Devices · Non Us 92 78 +17.9%
Medical Devices · Non Us 66 53 +24.5%
Medical Devices · Non Us 365 321 +13.7%
Medical Devices · Non Us 371 319 +16.3%
Medical Devices · Non Us 496 456 +8.8%
Medical Devices · Operating Segments 5,675 5,052 +12.3%
Medical Devices · Rhythm Management 705 624 +13.0%
Medical Devices · Structural Heart 675 609 +10.8%
Medical Devices · US 2,605 2,353 +10.7%
Medical Devices · US 843 734 +14.9%
Medical Devices · US 340 300 +13.3%
Medical Devices · US 283 253 +11.9%
Medical Devices · US 208 204 +2.0%
Medical Devices · US 340 303 +12.2%
Medical Devices · US 304 290 +4.8%
Medical Devices · US 287 269 +6.7%
Medical Devices · Vascular 783 725 +8.0%
Nutritionals · Adult Nutritionals 1,038 1,129 -8.1%
Nutritionals · Non Us 1,134 1,201 -5.6%
Nutritionals · Non Us 695 763 -8.9%
Nutritionals · Non Us 439 438 +0.2%
Nutritionals · Operating Segments 1,940 2,129 -8.9%
Nutritionals · Pediatric Nutritionals 902 1,000 -9.8%
Nutritionals · US 806 928 -13.1%
Nutritionals · US 343 366 -6.3%
Nutritionals · US 463 562 -17.6%
Show Geography breakouts
Non Us 7,076 6,633 +6.7%
US 4,383 4,341 +1.0%
US · Corporate Non Segment 5 5 0.0%
Show Consolidation Items breakouts
Corporate Non Segment 5 5 0.0%
Operating Segments 11,454 10,969 +4.4%
Cost of Revenue 4,922 4,942 -0.4%
Show Business Segments breakouts
Diagnostics · Operating Segments -8,650 -8,666 +0.2%
Established Pharmaceuticals · Operating Segments -4,529 -4,263 -6.2%
Medical Devices · Operating Segments -12,096 -11,187 -8.1%
Nutritionals · Operating Segments -8,071 -7,919 -1.9%
Show Consolidation Items breakouts
Operating Segments -33,346 -32,035 -4.1%
Total Costs & Expenses 9,208 9,063 +1.6%
Research & Development 735 749 -1.9%
Show Business Segments breakouts
Diagnostics · Operating Segments 147 174 -15.5%
Established Pharmaceuticals · Operating Segments 49 45 +8.9%
Medical Devices · Operating Segments 460 391 +17.6%
Nutritionals · Operating Segments 52 51 +2.0%
Show Consolidation Items breakouts
Operating Segments 708 661 +7.1%
Selling, General & Administrative 3,129 2,907 +7.6%
Show Business Segments breakouts
Diagnostics · Operating Segments 383 411 -6.8%
Established Pharmaceuticals · Operating Segments 377 327 +15.3%
Medical Devices · Operating Segments 1,387 1,259 +10.2%
Nutritionals · Operating Segments 435 490 -11.2%
Show Consolidation Items breakouts
Operating Segments 2,582 2,487 +3.8%
Operating Income 2,251 1,911 +17.8%
Show Business Segments breakouts
Diagnostics · Operating Segments 609 611 -0.3%
Established Pharmaceuticals · Operating Segments 255 271 -5.9%
Medical Devices · Operating Segments 1,978 1,773 +11.6%
Nutritionals · Operating Segments 386 443 -12.9%
Show Consolidation Items breakouts
Operating Segments 3,228 3,098 +4.2%
Interest Expense 120 136 -11.8%
Interest Income -78 -91 +14.3%
Other Non-Operating Income (Expense) -134 -154 +13.0%
Income Before Taxes 2,358 2,030 +16.2%
Income Tax Expense (Benefit) 582 -7,199 +108.1%
Net Income 1,776 9,229 -80.8%
Show Equity Components breakouts
Retained Earnings 1,776 9,229 -80.8%
Comprehensive Income 2,459 9,127 -73.1%
Other Comprehensive Income 683 -102 +769.6%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 683 -102 +769.6%
EPS (Basic) 1.01 5.28 -80.9%
EPS (Diluted) 1.02 5.26 -80.6%
Wtd Avg Shares (Basic) -1,739,876 -1,739,129 -0.0%
Wtd Avg Shares (Diluted) -1,747,413 -1,747,686 0.0%
Foreign Currency Transaction Gain Loss Before Tax -15 -10 -50.0%
Net Income Loss Available To Common Stockholders Basic 1.8 9.2 -80.4%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 8,522 7,616 +11.9%
Short-Term Investments 417 351 +18.8%
Accounts Receivable 7,929 6,925 +14.5%
Inventory 6,488 6,194 +4.7%
Total Current Assets 25,996 23,656 +9.9%
Non-Current Assets
Property, Plant & Equipment 11,816 10,658 +10.9%
Operating Lease Right-of-Use Assets 1,126 1,075 +4.7%
Goodwill 24,035 23,108 +4.0%
Show Business Segments breakouts
Diagnostics 3.6 — —
Established Pharmaceuticals 2.7 — —
Medical Devices 17.4 — —
Nutritionals 285 — —
Total Assets 86,713 81,414 +6.5%
Show Business Segments breakouts
Diagnostics · Operating Segments 8,273 7,678 +7.7%
Established Pharmaceuticals · Operating Segments 3,540 3,087 +14.7%
Medical Devices · Operating Segments 10,689 9,472 +12.8%
Nutritionals · Operating Segments 4,791 4,404 +8.8%
Show Consolidation Items breakouts
Operating Segments 27,293 24,641 +10.8%
Long Term Investments 918 886 +3.6%
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure · Equity Securities 597 553 +8.0%
Carrying Reported Amount Fair Value Disclosure · Other Aggregated Investments 321 333 -3.6%
Estimate Of Fair Value Fair Value Disclosure · Equity Securities 597 553 +8.0%
Estimate Of Fair Value Fair Value Disclosure · Other Aggregated Investments 321 333 -3.6%
Show Investment Type breakouts
Equity Securities 597 553 +8.0%
Other Investments 321 333 -3.6%
Current Liabilities
Current Portion of Long-Term Debt 3,033 1,500 +102.2%
Total Current Liabilities 16,496 14,157 +16.5%
Non-Current Liabilities
Long-Term Debt 9,896 12,625 -21.6%
Long-Term Debt 12,929 14,125 -8.5%
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure 12,929 14,125 -8.5%
Estimate Of Fair Value Fair Value Disclosure 12,772 13,710 -6.8%
Operating Lease Liabilities 931 896 +3.9%
Other Non-Current Liabilities 2,538 2,586 -1.9%
Stockholders' Equity
Common Stock 25,527 25,153 +1.5%
Retained Earnings 49,781 47,261 +5.3%
Accumulated Other Comprehensive Income -6,001 -7,906 +24.1%
Total Stockholders' Equity 52,130 47,664 +9.4%
Total Liabilities & Equity 86,713 81,414 +6.5%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Stock-Based Compensation 113 111 +1.8%
Change in Accounts Receivable 222 -158 +240.5%
Change in Inventory 234 235 -0.4%
Net Cash from Operations 3,315 2,868 +15.6%
Investing Activities
Capital Expenditures -689 -720 +4.3%
Other Investing Activities 6 4 +50.0%
Net Cash from Investing -913 -866 -5.4%
Financing Activities
Share Repurchases -302 -315 +4.1%
Net Cash from Financing -1,397 -1,861 +24.9%
Other Cash Flow
Net Change in Cash 1,011 58 +1643.1%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key